期刊文献+

恶性黑色素瘤86例临床病理分析 被引量:3

Clinicopathological analysis of 86 cases of malignant melanoma
下载PDF
导出
摘要 目的探讨86例恶性黑色素瘤的临床病理特点。方法收集86例恶性黑色素瘤的临床病理资料,在光镜下分析形态,采用VETENA自动免疫组化仪作相关抗体标记。结果恶性黑色素瘤细胞形态多样,可梭形、上皮样、未分化,可有或无色素,所有病例均表达HMB45、S-100、MelanA细胞抗原。结论恶性黑色素瘤是一种异质性很高的软组织肿瘤,其发病机制及治疗方法仍待深入。 Objective To explore clinicopathological features of 86 cases of malignant melanoma .Methods Eighty-six cases of malignant melanoma were collected and immuohistochemical stain was performed .Results The tumors were composed of a variety of cells ,such as epithelioid ,spindled ,or undifferentiated ,with or without colorings .All cases expressed HMB45 ,S-100 and Melan A .Conclusion Malignant melanoma is a high heterogeneous tumor that should be studied further in pathogenesis and therapy .
出处 《山西医药杂志》 CAS 2014年第19期2243-2244,共2页 Shanxi Medical Journal
基金 福建省自然基金(2012J01326) 福建省创新基金(2012-cx-7)
关键词 黑色素瘤 免疫组织化学 预后 Melanoma Immunohistoehemistry Prognosis
  • 相关文献

参考文献8

  • 1GOppner D, Ulrich J, Pokrywka A, et al. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors 2> 4.0 mm[J]. Dermatology, 2011, 222:59 -66. 被引量:1
  • 2Gershenwald JE, Soong SJ, Balch CM, et al. 2010 TNM staging system for cutaneous melanoma and beyond[J]. Ann Surg Oncol, 2010, 17( 6): 1475-1477. 被引量:1
  • 3朱鸿,董丹丹,李芳华,刘丹丹,王雷,傅静,宋林红,徐钢.非皮肤恶性黑色素瘤65例临床病理分析[J].临床与实验病理学杂志,2013,29(4):406-410. 被引量:11
  • 4Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [-J]. New Engl J Med,2010,363(8) :711 723. 被引量:1
  • 5王园园,王义善,王鑫,杨柯,杨桂青.PI3K/Akt信号通路与恶性黑色素瘤浸润转移的研究进展[J].实用医学杂志,2012,28(2):322-323. 被引量:7
  • 6Kostov M, Mijovi h Z, Mihailovi h D, et al. Correlation of cell cycle regulatory proteins [p53 and p16 (ink) 4 (a)] and bcl-2 oncoprotein with mitotic index and thickness of primary cuta neous malignant melanoma[J]. Bosh J Basic Med Sci, 2010, 10(4) : 276-281. 被引量:1
  • 7Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mu- tations in human lung cancer and melanoma[J]. Cancer Res, 2002,62(23) : 6997-7000. 被引量:1
  • 8Jeffrey Weber.恶性黑色素瘤的免疫治疗进展[J].中国肿瘤临床,2012,29(9):486-489. 被引量:13

二级参考文献51

  • 1束木娟,林梅绥,花井淳.不同部位恶性黑色素瘤DNA倍体分析和PCNA、p53蛋白的表达及其意义[J].临床与实验病理学杂志,2005,21(4):462-465. 被引量:5
  • 2胡蕾,姜汉国.PI3K/AKT信号转导通路与肿瘤转移及其机制的研究进展[J].医学综述,2006,12(22):1375-1377. 被引量:18
  • 3Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma European consensus based interdisciplinary guideline[J]. Eur J Cancer, 2010,46(2) :270-283. 被引量:1
  • 4Lin Y, Han C D, Mei S, et al. Akt/ protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt [J]. Cancer Res, 2004,64(13) :4394. 被引量:1
  • 5Alex T, Merav Y L. Akt Signaling and cancer surviving but not moving on[J]. Cancer Res, 2006,66(9) :3963-3966. 被引量:1
  • 6Hara S, Oya M, Mizuno R, et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor [J]. Ann Oncol, 2005,16(6) :928. 被引量:1
  • 7Brick A, Ahrenkiel V, Zenthen J, et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies [J]. J Invest Dermatol, 2000,114(2) :227-280. 被引量:1
  • 8Risinger J I, Hayes K, Maxwell G L,et al. PTEN mutation in endometrial cancer is associated with favorable clinical andpathologic characteristics [J]. Clin Cancer Res, 1998,4(12) : 3005. 被引量:1
  • 9Cantl Eylc, Neel B G. New insights into tumor suppression: HEN suppresses tumor formation by restraining thephosphoinositide 3-kinase/ AKT pathway [J]. Proc Natl Acad Sci USA, 1999, 96(8) :4240-4245. 被引量:1
  • 10Huang S, Houghton P J. Targeting mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol, 2003,3(4) :371- 377. 被引量:1

共引文献28

同被引文献23

  • 1Bradford PT,Gold Stein AM,McMaster ML,et al.Acral lentiginous melanoma incidence and survival patterns in the United States,1986-2005[J].Arch Dermatol,2009,145(4):427-434. 被引量:1
  • 2Mackie RM,Bray C,Vestey J,et al.Melanoma incidence and mortality in Scotland 1979-2003[J].Br J Cancer,2007,96(11):1772-1777. 被引量:1
  • 3Hodi FS,O'Day SJ,McDermott DF,et al.Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723. 被引量:1
  • 4Brose MS,Volpe P,Feldman M,et al.BRAF and RAS mutations in human lung cancer and melanoma[J].Cancer Res,2002,62(23):6997-7000. 被引量:1
  • 5Smalley KS.PLX-4032,a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma[J].Curr Opin Investig Drugs,2010,11(6):699-706. 被引量:1
  • 6Gppner D,Ulrich J,Pokrywka A,et al.Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors>4.0mm[J].Dermatology,2011,222(1):59-66. 被引量:1
  • 7Gershenwald JE,Soong S,Balch CM,et al.2010TNM staging system for cutaneous melanoma and beyond[J].Ann Surg Oncol,2010,17(6):1475-1477. 被引量:1
  • 8周茜,黄绮,姚晓虹,祝明洁,蒋允凯.29例皮肤恶性黑色素瘤临床病理分析[J].中国医药指南(学术版),2008,6(9):20-22. 被引量:10
  • 9胡健,常栋,龚民,田锋.原发性食管恶性黑色素瘤临床病理特征及治疗[J].中华医学杂志,2010,90(25):1785-1787. 被引量:11
  • 10迟志宏,盛锡楠,李思明,崔传亮,斯璐,郭军.357例中国皮肤黑色素瘤临床特征与预后分析[J].肿瘤防治研究,2011,38(11):1316-1319. 被引量:14

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部